ALT 836

Drug Profile

ALT 836

Alternative Names: ALT-836; cH36; Sunol-cH36; TNX 832

Latest Information Update: 26 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sunol Molecular Corporation
  • Developer Altor BioScience Corporation
  • Class Anti-inflammatories; Anticoagulants; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Factor IX inhibitors; Factor X inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury; Adult respiratory distress syndrome
  • Phase I Solid tumours
  • Preclinical Coeliac disease; Inflammatory bowel diseases
  • Discontinued Thrombosis

Most Recent Events

  • 31 Jul 2015 Phase-II development is ongoing for Acute lung injury and Adult respiratory distress syndrome in USA
  • 24 May 2011 Altor BioScience receives SBIR grant from National Heart Lung and Blood Institute for ALT 836 development in Acute lung injury and Adult respiratory distress syndrome
  • 22 Nov 2010 ALT 836 is still in active development for Acute lung injury/Adult respiratory distress syndrome and Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top